| 1. |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30.
|
| 2. |
Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res, 2018, 30(1): 1-12.
|
| 3. |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
|
| 4. |
張太平, 曹喆, 趙玉沛. 多學科診療模式在胰腺癌綜合診治決策中的價值. 中國普外基礎與臨床雜志, 2017, 24(6): 665-667.
|
| 5. |
Katz MH, Kim MP, Tzeng CW, et al. Preoperative chemoradiation for borderline resectable pancreatic cancer: the new standard? Ann Surg, 2018, [Epub ahead of print].
|
| 6. |
梁廷波, 白雪莉, 李想. 胰腺癌新輔助治療的進展及面臨的問題. 中國普外基礎與臨床雜志, 2017, 24(6): 657-660.
|
| 7. |
Asada S, Itaya H, Nakamura K, et al. Radical pancreatoduodenectomy and portal vein resection. Report of two successful cases with transplantation of portal vein. Arch Surg, 1963, 87: 609-613.
|
| 8. |
Allema JH, Reinders ME, van Gulik TM, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg, 1994, 81(11): 1642-1646.
|
| 9. |
Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg, 1996, 223(2): 154-162.
|
| 10. |
Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg, 1998, 85(5): 611-617.
|
| 11. |
Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg, 2004, 8(8): 935-949.
|
| 12. |
Kitagawa H, Ohta T, Tajima H, et al. En bloc resection including the superior mesenteric artery and vein of locally advanced pancreatic carcinomas. Nihon Geka Gakkai Zasshi, 2011, 112(3): 164-169.
|
| 13. |
Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol, 2008, 15(6): 1651-1660.
|
| 14. |
Varadhachary GR, Tamm EP, Crane C, et al. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol, 2005, 8(5): 377-384.
|
| 15. |
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol, 2006, 13(8): 1035-1046.
|
| 16. |
Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol, 2014, 20(31): 10740-10751.
|
| 17. |
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(8): 1028-1061.
|
| 18. |
中國抗癌協會胰腺癌專委會. 胰腺癌綜合診治指南 (2018 版). 2018-04. http://guide.medlive.cn/guideline/15566..
|
| 19. |
Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008, 206(5): 833-846.
|
| 20. |
Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology, 2018, 18(1): 2-11.
|
| 21. |
Hayasaki A, Isaji S, Kishiwada M, et al. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer. Cancers (Basel), 2018, 10(3): E65.
|
| 22. |
Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9≥1 000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9): 2216-2227.
|
1/5
WeChat